391 related articles for article (PubMed ID: 26043214)
1. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
2. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
Eisenhardt N; Chaugule VK; Pichler A
Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
[TBL] [Abstract][Full Text] [Related]
3. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
4. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity.
Sentis S; Le Romancer M; Bianchin C; Rostan MC; Corbo L
Mol Endocrinol; 2005 Nov; 19(11):2671-84. PubMed ID: 15961505
[TBL] [Abstract][Full Text] [Related]
5. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
6. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
7. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
8. Dynamin interacts with members of the sumoylation machinery.
Mishra RK; Jatiani SS; Kumar A; Simhadri VR; Hosur RV; Mittal R
J Biol Chem; 2004 Jul; 279(30):31445-54. PubMed ID: 15123615
[TBL] [Abstract][Full Text] [Related]
9. The SUMO components in rheumatoid arthritis.
Wu Q; Jiang Y; You C
Rheumatology (Oxford); 2022 Nov; 61(12):4619-4630. PubMed ID: 35595244
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
[TBL] [Abstract][Full Text] [Related]
11. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
[TBL] [Abstract][Full Text] [Related]
12. Sumoylation and Its Contribution to Cancer.
Lee JS; Choi HJ; Baek SH
Adv Exp Med Biol; 2017; 963():283-298. PubMed ID: 28197919
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of the Recombinant RanBP2 SUMO E3 Ligase Complex.
Ritterhoff T; Das H; Hao Y; Sakin V; Flotho A; Werner A; Melchior F
Methods Mol Biol; 2016; 1475():41-54. PubMed ID: 27631796
[TBL] [Abstract][Full Text] [Related]
14. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
15. Starting and stopping SUMOylation. What regulates the regulator?
Watts FZ
Chromosoma; 2013 Dec; 122(6):451-63. PubMed ID: 23812602
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells.
Huang CH; Yang TT; Lin KI
J Biomed Sci; 2024 Jan; 31(1):16. PubMed ID: 38280996
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk.
Dünnebier T; Bermejo JL; Haas S; Fischer HP; Pierl CB; Justenhoven C; Brauch H; Baisch C; Gilbert M; Harth V; Spickenheuer A; Rabstein S; Pesch B; Brüning T; Ko YD; Hamann U
Breast Cancer Res Treat; 2010 May; 121(1):185-94. PubMed ID: 19760037
[TBL] [Abstract][Full Text] [Related]
18. PIASγ controls stability and facilitates SUMO-2 conjugation to CoREST family of transcriptional co-repressors.
Sáez JE; Arredondo C; Rivera C; Andrés ME
Biochem J; 2018 Apr; 475(8):1441-1454. PubMed ID: 29555846
[TBL] [Abstract][Full Text] [Related]
19. Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.
Truong K; Lee TD; Chen Y
J Biol Chem; 2012 May; 287(19):15154-63. PubMed ID: 22403398
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a C-Terminal SUMO-Interacting Motif Present in Select PIAS-Family Proteins.
Lussier-Price M; Mascle XH; Cappadocia L; Kamada R; Sakaguchi K; Wahba HM; Omichinski JG
Structure; 2020 May; 28(5):573-585.e5. PubMed ID: 32348746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
